<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="130969">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01707277</url>
  </required_header>
  <id_info>
    <org_study_id>EMI</org_study_id>
    <nct_id>NCT01707277</nct_id>
  </id_info>
  <brief_title>The Effects of Inspiratory Muscle Training in Patients With Heart Failure With Preserved Ejection Fraction</brief_title>
  <official_title>The Effects of Inspiratory Muscle Training in Patients With Heart Failure With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Valencia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación para la Investigación del Hospital Clínico de Valencia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Valencia</source>
  <oversight_info>
    <authority>Spain: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous studies have evaluated the effects of inspiratory muscle training in patiens with
      heart failure and reduced ejection fraction; nevertheless,no evidence endorse the
      therapeutic role of inspiratory muscle training in patients with heart failure and preserved
      ejection fraction. The investigators sought to evaluate whether 12-week inspiratory muscle
      training improves exercise capacity (peak exercise oxygen uptake and 6-minutes walk test),
      as well as left ventricular diastolic function, serum biomarkers and quality of life
      (Minnesota Living With Heart Failure Questionnaire) in patients with heart failure with
      preserved ejection fraction and non-reduced inspiratory muscle strength.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Changes in exercise capacity parameters at 12-weeks.</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Exercise parameters: peak exercise oxygen uptake (peak VO2), 6-minutes walk test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in 12-week quality of life,  biomarkers related to the severity and parameters of left ventricular diastolic function.</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quality of life: Minnesota Living With Heart Failure Questionnaire. Biomarkers: plasma natriuretic peptides, estimaated glomerular filtration rate, antigen carbohydrate 125.
Diastolic function: E/e´.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Inspiratory muscle training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inspiratory muscle training for improving maximum inspiratory pressure plus phrmacological treatment Pharmacological treatment (usual care)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pharmacological treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Inspiratory muscle training</intervention_name>
    <description>Patients were instructed to train at home twice daily for 20 minutes each session during 12 weeks with a threshold inspiratory muscle trainer (Threshold IMT®, Respironics Inc.). All of them were trained under the supervision of a physiotherapist and educated to maintain diaphragmatic breathing during training. The subjects started breathing at a resistance equal to 25-30% of their maximum inspiratory pressure for 1 week.</description>
    <arm_group_label>Inspiratory muscle training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual care</intervention_name>
    <description>Usual pahramacological treatment</description>
    <arm_group_label>Inspiratory muscle training</arm_group_label>
    <arm_group_label>Usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a) previous history of symptomatic heart failure (New York Heart Association [NYHA]
             functional class ≥II)

          -  b) evidence of normal left ventricular ejection fraction, defined by an ejection
             fraction &gt;0.50 and an end-diastolic diameter &lt;60 mm by 2D echocardiography

          -  c) relevant structural heart disease (left ventricle hypertrophy/left atrial
             enlargement) and/or diastolic dysfunction estimated by 2D echocardiography

          -  d) clinical stability, including no admissions in the past 30 days

        Exclusion Criteria:

          -  a) Patients unable to perform a valid baseline exercise test.

          -  b) Unstable angina, myocardial infarction or cardiac surgery within the previous
             three months.

          -  c)Known chronic metabolic, orthopedic, infectious disease or previous pulmonary
             disease;

          -  d)Treatment with steroids, hormones, or cancer chemotherapy;

          -  e)Reduced maximal inspiratory pressure according to age and sex;

          -  f)Active smokers

          -  g)Acute decompensation;

          -  h)Other comorbidity with an expectancy of life less than one year
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julio Núñez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Valencia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínico Universitario</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Lin SJ, McElfresh J, Hall B, Bloom R, Farrell K. Inspiratory muscle training in patients with heart failure: a systematic review. Cardiopulm Phys Ther J. 2012 Sep;23(3):29-36.</citation>
    <PMID>22993500</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 12, 2012</lastchanged_date>
  <firstreceived_date>October 9, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Valencia</investigator_affiliation>
    <investigator_full_name>Julio Núñez,MD</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Heart failure with preserved ejection fraction</keyword>
  <keyword>Inspiratory muscle training</keyword>
  <keyword>Exercise capacity</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
